# Semaglutide Dose Escalation and Insulin Reduction in Type 2 Diabetes | This GLP In 62 patients, total daily insulin fell 5.6%, 22.2% and 36.9% across semaglutide dose steps while HbA1c dropped from 7.7% to 7.1%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/each-dose-step-took-insulin-away Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Semaglutide Dose Escalation and Insulin Reduction in Type 2 Diabetes In a 62-patient chart review, total daily insulin fell by 36.9% as semaglutide was escalated to 2 mg, and HbA1c improved rather than slipped. The published confidence intervals do not parse. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Total daily insulin, against baseline · at 1 mg · −5.6% · at 2 mg · −22.2% · 3 months at 2 mg · −36.9% · 62 patients, one VA center, no control group. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A chart review of 62 patients with type 2 diabetes tracked total daily insulin as semaglutide was escalated from 0.5 mg to 2 mg. - Insulin fell 5.6% by the 1 mg step (P = .008), 22.2% by the 2 mg step (P < .001), and 36.9% after at least three months at 2 mg (P < .001). - HbA1c fell from 7.7% to 7.1% over the same period, so glycemic control improved while insulin came down. - Confidence intervals as printed in the source do not bracket their own point estimates, so only the percentage changes and P values are reported here. Insulin is the treatment people most want to reduce: it requires more frequent dosing, it causes hypoglycemia, and it drives weight gain. Whether escalating a GLP-1 drug lets people take less of it is a practical question, and a chart review at a Veterans Affairs center followed 62 patients through the dose steps to find out [\[1\]](https://thisglp.com/research/each-dose-step-took-insulin-away#ref-1). Swapping mealtime doses entirely is a different question, and this chart review does not answer it. The pattern is stepwise. Total daily insulin fell 5.6% by the time the 1 mg dose started, and 22.2% by the 2 mg step, and 36.9% after at least three months at 2 mg. HbA1c went from 7.7% to 7.1% across the same period, which is the combination that matters: less insulin and better control, not one traded for the other. What the same drugs do to weight across that stretch is pooled in [the weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average). The intervals in the source do not parse The paper reports each change with a confidence interval that is positive while the estimate is negative, and in two cases the estimate falls outside its own interval. That is a sign or typesetting failure rather than data, so nothing is derived from those intervals here — the percentage changes and P values are reported and the intervals are not. A reader should treat the precision of these figures as unstated rather than as given. A monotonic relationship across three dose steps is more persuasive than a single before-and-after comparison would be, because a confounder would have to track the escalation schedule to produce it. That is the strongest thing about this study, and it is working against real limitations: 62 patients at one center, retrospective, with no control group and no way to separate the drug from everything else that changes over months of active diabetes management. One detail matters for anyone reading across from the weight literature. Semaglutide 2 mg is a diabetes dose with a diabetes label; the weight-management product is 2.4 mg and is a different prescription. The dose question generally is set out in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated), and what happens at the top of the ladder in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The practical implication is worth stating plainly because it is easy to miss: if insulin requirements fall by a third, insulin doses must be actively reduced as the GLP-1 dose rises, or hypoglycemia follows. That is a prescriber’s job and not a thing to manage alone, which is one more reason the variable clinical support described in [the analysis in older adults](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults) and the monitoring gaps in [vitamins and minerals on a GLP-1](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1) matter more than they appear to. ## Frequently asked Does a GLP-1 reduce how much insulin you need? In this small review, total daily insulin fell progressively with each semaglutide dose step, reaching 36.9% below baseline after three months at 2 mg, while HbA1c also improved. Is the finding reliable? It is suggestive rather than established. Sixty-two patients at one center, retrospective and without a control group — though the stepwise pattern across three dose levels is harder to explain by chance than a single comparison. Does insulin need adjusting when starting one? If requirements fall this much, doses have to come down alongside, or hypoglycemia follows. That is a prescriber's decision and not something to manage without supervision. ## Sources 1. \[1\] Halver A, Wiksen J, Larson A, Wegner A (2025). Efficacy of Subcutaneous Semaglutide Dose Escalation in Reducing Insulin in Patients With Type 2 Diabetes Federal Practitioner. [PMID 42666995](https://pubmed.ncbi.nlm.nih.gov/42666995/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)